Search Results

An Interview With Firas F. Mussa, MD, MS, FACS

Dr. Mussa shares his insights on the future of TEVAR for uncomplicated type B aortic dissection, percutaneous EVAR, and treatment options for CLI.

IMPROVE-AD: Rationale and Progress to Date

Dr. Firas F. Mussa talks about the goals of IMPROVE-AD, its design and what makes it unique, how funding was obtained, the role of the patient advocacy group, and more.

Tips for a New Hire: Don't Repeat My Mistakes

By Firas F. Mussa, MD

Fellows Debate: Access for EVAR

Percutaneous or femoral artery cutdown? A debate from the multispecialty conference at the Texas Medical Center.

By Firas F. Mussa, MD; James H. Mitchell, MD; Joseph J. Naoum, MD; Zvonimir Krajcer, MD; and Alan B. Lumsden, MD

Determining Cost-Effectiveness in CLI Therapy

Weighing clinical benefits along with cost when selecting therapies is more important than ever.

By Firas F. Mussa, MD, MS, with commentary by Mary L. Yost, MBA

Endovascular Exclusion of Carotid Stump Syndrome

How endovascular intervention can be a viable option for treating this rare condition.

By Kate Rooney, BS; Thomas S. Maldondo, MD; and Firas F. Mussa, MD

One Question ... What is your preferred closure method for standard percutaneous revascularization procedures performed via femoral access?

With Firas F. Mussa, MD, MS, FACS; Stephen Kee, MD; Richard C. Kovach, MD, FACC, FACP; and Jaafer Golzar, MD, FACC, FSCAI

One Question . . .

If you perform TEVAR to treat acute type B dissection, do you use IVUS during the procedure?

By Manish Mehta, MD; Ross Milner, MD; Michael D. Dake, MD; Edward Y. Woo, MD; and Firas F. Mussa, MD

Tailored Thoracic Aortic Repair

By Jordan R. Stern, MD

CLI: Where We Stand

By Jihad A. Mustapha, MD

The Venous Challenge

By Barry T. Katzen, MD